Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "ultra low dose naltrexone":

Search results

Items: 19

1.

Oxycodone combined with opioid receptor antagonists: efficacy and safety.

Davis M, Goforth HW, Gamier P.

Expert Opin Drug Saf. 2013 May;12(3):389-402. doi: 10.1517/14740338.2013.783564. Epub 2013 Mar 28. Review.

PMID:
23534906
2.

Does adding low doses of oral naltrexone to morphine alter the subsequent opioid requirements and side effects in trauma patients?

Farahmand S, Ahmadi O, Dehpour A, Khashayar P.

Am J Emerg Med. 2012 Jan;30(1):75-8. doi: 10.1016/j.ajem.2010.09.031. Epub 2010 Nov 13.

PMID:
21075578
3.

Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.

Hay JL, La Vincente SF, Somogyi AA, Chapleo CB, White JM.

Eur J Pain. 2011 Mar;15(3):293-8. doi: 10.1016/j.ejpain.2010.07.009. Epub 2010 Aug 21.

PMID:
20728384
4.

PTI-609: a novel analgesic that binds filamin A to control opioid signaling.

Burns LH, Wang HY.

Recent Pat CNS Drug Discov. 2010 Nov;5(3):210-20. Review.

PMID:
20726836
5.

Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.

Mattioli TA, Milne B, Cahill CM.

Mol Pain. 2010 Apr 16;6:22. doi: 10.1186/1744-8069-6-22.

6.

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.

Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE.

Psychopharmacology (Berl). 2010 Jul;210(4):471-80. doi: 10.1007/s00213-010-1838-3. Epub 2010 Apr 13.

7.

Tolerance to the anticonvulsant effect of morphine in mice: blockage by ultra-low dose naltrexone.

Roshanpour M, Ghasemi M, Riazi K, Rafiei-Tabatabaei N, Ghahremani MH, Dehpour AR.

Epilepsy Res. 2009 Feb;83(2-3):261-4. doi: 10.1016/j.eplepsyres.2008.10.011. Epub 2008 Dec 6.

PMID:
19059761
9.

The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice.

Bahremand A, Shafaroodi H, Ghasemi M, Nasrabady SE, Gholizadeh S, Dehpour AR.

Epilepsy Res. 2008 Sep;81(1):44-51. doi: 10.1016/j.eplepsyres.2008.04.010. Epub 2008 May 27.

PMID:
18502613
10.

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW.

J Pain. 2008 Aug;9(8):700-13. doi: 10.1016/j.jpain.2008.03.005. Epub 2008 May 12.

11.

Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice.

Gholizadeh S, Shafaroodi H, Ghasemi M, Bahremand A, Sharifzadeh M, Dehpour AR.

Neuropharmacology. 2007 Nov;53(6):763-70. Epub 2007 Aug 15.

PMID:
17870135
13.

Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.

Webster LR.

Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83. Review.

PMID:
17685875
14.

Ultra-low dose naltrexone enhances cannabinoid-induced antinociception.

Paquette J, Olmstead MC.

Behav Pharmacol. 2005 Dec;16(8):597-603. Erratum in: Behav Pharmacol. 2007 Nov;18(7):705. Olmstead, Mary [corrected to Olmstead, Mary C].

PMID:
16286810
15.

Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats.

Leri F, Burns LH.

Pharmacol Biochem Behav. 2005 Oct;82(2):252-62. Epub 2005 Sep 21.

PMID:
16182352
16.

Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats.

Olmstead MC, Burns LH.

Psychopharmacology (Berl). 2005 Sep;181(3):576-81. Epub 2005 Oct 12.

PMID:
16010543
17.

Ultra-low dose naltrexone potentiates the anticonvulsant effect of low dose morphine on clonic seizures.

Honar H, Riazi K, Homayoun H, Sadeghipour H, Rashidi N, Ebrahimkhani MR, Mirazi N, Dehpour AR.

Neuroscience. 2004;129(3):733-42.

PMID:
15541894
19.

Supplemental Content

Loading ...
Support Center